|Previous Section||Index||Home Page|
Mr. Hands: To ask the Secretary of State for Health what the average number of occupied bed days was for patients admitted to hospitals with congestive heart failure in each of the last five years. 
|Mean and median bed days during the year for finished admissions episodes with a primary diagnosis of 150.0 Congestive Heart Failure for 2001-02 to 2005-06NHS hospitals, England|
1. ICD-10 Code: I50.0 Congestive Heart Failure
2. Bed Days During the Year
Bed days within the year include only those days falling between 1 April and 31 March of the data year including unfinished episodes, unless otherwise stated.
3. Diagnosis (Primary Diagnosis)
The primary diagnosis is the first of up to 14 (seven prior to 2002-03) diagnosis fields in the Hospital Episode Statistics (HES) data set and provides the main reason why the patient was in hospital.
4. Data Quality
HES are compiled from data sent by over 300 national health service trusts and primary care trusts (PCTs) in England. The Information Centre for health and social care liaises closely with these organisations to encourage submission of complete and valid data and seeks to minimise inaccuracies and the effect of missing and invalid data via HES processes. While this brings about improvement over time, some shortcomings remain.
5. Assessing growth through time
HES figures are available from 1989-90 onwards. During the years that these records have been collected the NHS there have been ongoing improvements in quality and coverage. These improvements in information submitted by the NHS have been particularly marked in the earlier years and need to be borne in mind when analysing time series.
Changes in NHS practice also need to be borne in mind when analysing time series. For example a number of procedures may now be undertaken in outpatient settings and may no longer be accounted in the HES data. This may account for any reductions in activity over time.
Figures have not been adjusted for shortfalls in data (ie the data are ungrossed).
HES, The Information Centre for health and social care
Tim Farron: To ask the Secretary of State for Health how many hospital trusts are not in compliance with the Royal College of Physicians guidelines on consultants working at more than one hospital. 
Mr. Stephen O'Brien: To ask the Secretary of State for Health how many and what percentage of hospital main meals were left untouched in (a) England and (b) each NHS provider organisation in each year from 2001-02 to 2006-07; and if he will make a statement. 
Ann Keen: Information on the number, and percentage, of hospital main meals left untouched in England is in the following table. Information relating to individual national health service providers has been placed in the Library. Data were not collected before 2001-02.
|England||Total number untouched/unserved patient meals||Average percentage untouched/unserved patient meals|
Food is left untouched or unserved for a variety of reasons, but generally a combination of sufficient food being provided in order to ensure patients have a choice and changing requirements, i.e. patients being discharged or moved, being absent for treatment or changing clinical status after the food orders have been made.
Information on age has only been collected under the mandatory surveillance scheme by the Health Protection Agency (HPA) since October 2005 and the latest data were published on 25 July 2007. The total number of cases of MRSA bloodstream infections in the 12 months from April 2006 to March 2007 in children aged under one year in England was 35.
The HPAs voluntary reporting scheme collects data on age and sex of cases. The scheme does not collect data on where infection was acquired (e.g. neonatal unit, or maternity unit). The following table shows the number of cases of Clostridium difficile for children from birth to one in England, Wales and Northern Ireland for 2005. Data for 2006 are not available yet.
The aforementioned information is likely to be an underestimate as not all laboratories report. Furthermore, testing of children under two years of
age may be limited owing to a general belief that the presence of C. difficile is not usually clinically significant in this age group as asymptomatic carriage, including production of toxins A and B, is common in this age group.
Sandra Gidley: To ask the Secretary of State for Health pursuant to the answer of 18 July 2007, Official Report, column 456W, on hospitals: infectious diseases, in how many hospitals the six deaths in 2005 took place. 
Mr. Rob Wilson: To ask the Secretary of State for Health (1) how many hospitals were opened with private finance initiative funding since 1997, broken down by strategic health authority region; 
|Capital value of PFI schemes opened or commenced construction in each of last five years|
|Strategic health authority||PFI schemes operational since 1997||2003||2004||2005||2006||2007 (to date)||Total|
Sandra Gidley: To ask the Secretary of State for Health if he will take steps to ensure that clear guidance is given to primary care trusts on how girls can access human papilloma virus vaccines outside (a) vaccination and (b) catch-up programmes. 
Sandra Gidley: To ask the Secretary of State for Health whether the Joint Committee on Vaccination and Immunisation expects to provide a recommendation to Ministers on a potential human papilloma virus vaccination catch-up programme for girls beyond the age of 13, following its meeting in October 2007. 
Dawn Primarolo: A detailed analysis is being carried out by the Joint Committee on Vaccination and Immunisation (JCVI) regarding the benefits and costs of introducing a human papilloma virus vaccine programme. This work is being externally peer reviewed to ensure its robustness. This review has not yet been completed and therefore JCVI will not be able to make its more detailed recommendation, including whether there will be a catch-up for older girls, until after its next meeting, on October 17.
Sandra Gidley: To ask the Secretary of State for Health which body will be completing the independent peer review of the cost benefit analysis for human papilloma virus vaccination; and when this review is due to be completed. 
Dawn Primarolo: A detailed analysis is being carried out by the Joint Committee on Vaccination and Immunisation (JCVI) regarding the benefits and costs of introducing a human papilloma virus (HPV) vaccine programme. This work is being externally peer reviewed by biologists working in the HPV field, mathematical modellers and economists in order to ensure its robustness.
Sandra Gidley: To ask the Secretary of State for Health how he will involve primary care trusts and strategic health authorities in planning for implementation of a human papilloma virus vaccination programme in autumn 2008. 
Dawn Primarolo: The introduction of a comprehensive nationwide human papilloma virus vaccine programme will be a considerable undertaking for the national health service and many practical issues need to be discussed with stakeholders, particularly from the NHS. The Department will work with stakeholders, including primary care trusts and strategic health authorities, to plan for the introduction of the vaccine.
|Next Section||Index||Home Page|